Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

BACKGROUND: The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events (irAEs) including colitis. We aimed to estimate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Drug Saf
Hauptverfasser: Almutairi, Abdulaali R., Slack, Marion, Erstad, Brian L., McBride, Ali, Abraham, Ivo
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970695/
https://ncbi.nlm.nih.gov/pubmed/33796257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098621991279
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge